With a full dataset now illustrating success for a deuterated formulation of ruxolitinib in alopecia areata, Concert Pharmaceuticals Inc. continues to believe its selective JAK1/2 inhibitor is on pace to get to market first in the unmet medical need, ahead of Pfizer Inc.’s competing Phase II candidate, selective JAK3 inhibitor PF-06651600.
Concert unveiled new data from its Phase II dose-ranging study of CTP-543 on 3 September, showing that a 12mg twice-daily...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)